SCHEMBL24849671

SCHEMBL24849671

CNS(=O)(=O)Nc1nccc(Cc2cc(C(N)=O)c(Nc3ccc(C)cc3F)cn2)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2K1 Q02750 7/20 0.40
▸ MAP2K2 P36507 3/20 0.40
▸ CSF1R P07333 2/20 0.39
▸ RAF1 P04049 4/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ BRAF P15056 1/20 0.37
▸ MAP2K5 Q13163 1/20 0.37
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ KCNH2 Q12809 2/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ DHODH Q02127 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23693880 0.91 MAP2K1 (0.42) MAP2K1MAP2K2BRAF
SCHEMBL29425298 0.91 MAP2K1 (0.42) MAP2K1MAP2K2BRAF
SCHEMBL26330721 0.91 MAP2K1 (0.38) MAP2K1MAP2K2CSF1RRAF1CYP2C9
SCHEMBL24849393 0.88 MAP2K1 (0.43) MAP2K1MAP2K2CSF1RRAF1CYP2C9
SCHEMBL23693891 0.86 CSF1R (0.42) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL24849400 0.84 CSF1R (0.41) MAP2K1MAP2K2CSF1RRAF1CYP2C9
SCHEMBL26330725 0.82 MAP2K1 (0.39) MAP2K1MAP2K2RAF1CYP2C9BRAF
SCHEMBL23693716 0.81 MAP2K1 (0.41) MAP2K1MAP2K2CSF1RRAF1CYP2C9
SCHEMBL24848965 0.80 MAP2K1 (0.42) MAP2K1MAP2K2CSF1RRAF1CYP2C9
Hydrogen Sulfide SCHEMBL24927904 0.80 CSF1R (0.37) MAP2K1MAP2K2CSF1RHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS MAP2K1 162/4885MAP2K2 132/4885CSF1R 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback